Drug intelligence / Profile preview

paroxetine

Development stage
Approved
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It works by inhibiting the reuptake of serotonin in the brain, thereby increasing serotonin levels and improving mood and anxiety symptoms. Paroxetine is primarily indicated for major depressive disorder but is also approved for panic disorder, obsessive-compulsive disorder (OCD), social anxiety disorder, generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and vasomotor symptoms of menopause such as hot flashes. It was first approved in the United States in 1992 and has since become widely prescribed globally[2][4][5][6][7]. Paroxetine is known for its high selectivity and potency among SSRIs but may be associated with withdrawal effects upon discontinuation[5].

Brand names
PaxilPaxil CRPexevaBrisdelleSeroxatAropaxSereupin
Other names
paroxetine帕罗西汀
02

Targets

CYP2B6 (Cytochrome P450 2B6)CYP2D6 (Cytochrome P450 2D6)SERT (Sodium-dependent serotonin transporter)CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on paroxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paroxetine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call